Skip to main content
Delfa

← Trials/Trial dossier/NCT04663854

MASHIANE

UnknownPhase 1

Mycose AdminiStration for HealIng Alzheimer NEuropathy (MASHIANE)

Evaluation of the Therapeutic Effects of Trehalose in Patients With Alzheimer Disease

Asset

Trehalose

Listed sites

1

Recruiting sites

1

Enrollment

20

estimated

Study population

Alzheimer’s disease

Key I/E criterion

•MMSE 10-23

Primary endpoints

•Mini-Mental State Examination (MMSE)•Changes in Clinical Dementia Rating Scale (CDR)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID971659
NCT IDNCT04663854

Timeline

Milestones

Study start2020-08-20actual
Study first posted2020-12-11actual
Last update posted2020-12-11actual
Primary completion2022-03-20estimated
Study completion2022-08-20estimated

Assets

Drug assets

Trehalose

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Mini-Mental State Examination (MMSE) score range from 10 to 23
•Not having other cognitive disorders

Exclusion criteria

•MMSE score higher than 23 or lower than 10
•The presence of other cognitive disorders which will be evaluated by clinical assessment and brain imaging
•The presence of factors affecting cognitive impairment such as depression
•Vascular dementia and Lewy body dementia
•Previous history of head trauma
•Use of alcohol and other drugs that affect cognitive functioning

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Global cognition

2 endpoints
Primary/protocol endpoint

Changes of Mini-Mental State Exam (MMSE)

Time frame:From baseline to 12 weeks

Mini-Mental State Examination (MMSE)

descriptive

Primary/protocol endpoint

Changes in Clinical Dementia Rating Scale (CDR)

Time frame:From baseline to 12 weeks

descriptive

Publications (12)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.